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Abstract
Background/Aims: Chronic renal proximal tubule dysfunction after therapy with the 
antineoplastic agent ifosfamide (IFO) is often attributed to the metabolite chloroacetaldehyde 
(CAA). Chronic IFO-nephropathy is reported to result in tubulointerstitial fibrosis and 
inflammation. Methods: To elucidate possible effects of CAA on extracellular matrix 
homeostasis, we investigated the action of CAA on markers of extracellular matrix (ECM) 
homeostasis in human proximal tubule cells (RPTEC) by use of direct ELISA for extracellular 
collagens and gelatin zymography. Results: An increase in type III collagen and a decrease in 
type IV collagen abundance in the media of RPTEC could be observed after exposure to CAA in 
clinically relevant concentrations. CAA increased intracellular type III and decreased intracellular 
type IV collagen. MMP-2 activity was decreased but MMP-9 activity unchanged. The enhanced 
CAA-induced collagen III formation could be attenuated by the intracellular Ca2+-chelator 
BAPTA-AM, the PKA-antagonist H-89 and by extracellular acidification. CAA-induced collagen 
III abundance was enhanced by db-cAMP and IBMX and by protein overload. Conclusions: 
CAA exerts profibrotic effects on RPTEC dependent on Ca2+ and cAMP/PKA-signaling. These 
effects are enhanced by additional protein burden and attenuated by acidification.
Introduction
Chloroacetaldehyde (CAA) is a metabolite of the cancer therapeutic ifosfamide (IFO) 
generated mainly in liver by cytochrome P450-dependent mechanisms [1]. IFO is included 
in therapy protocols for the treatment of malignant solid tumors, especially in pediatric 
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oncology, with response rates up to 80 % [2]. Yet, there is a significant number of patients 
developing chronic renal dysfunction, sometimes even years after the end of treatment 
[3, 4]. The predominant target for IFO-induced renal disease is the proximal tubule [5, 6]. 
The severity of renal impairment ranges from mild renal tubular acidosis (in up to 40% 
of all patients) to full blown Fanconi-syndrome (in up to 5 % of all patients) [3, 7, 8]. In 
pediatric patients treated with IFO wasting of phosphate by damaged proximal tubules often 
requires phosphate substitution to prevent hypophosphatemic rickets [3]. Additionally, the 
toxic effects of IFO treatment can persist over a long time period in children [9]. Thus, renal 
toxicity of IFO is of concern in oncology patients and especially in children. Until now, there 
are few prognostic parameters to identify patients who will develop chronic nephrotoxicty, 
since acute and chronic damage are not well correlated [10]. Furthermore, the mechanisms 
by which IFO leads to proximal tubular damage are poorly understood. Among IFO and its 
metabolites, CAA is most probably responsible for chronic renal disease [11-14]. Cell culture 
studies could show impairment of several transport mechanisms by CAA in renal proximal 
tubule cells and a concentration-dependent necrotic rather than apoptotic cell death [15-
19]. Recently we could provide evidence for cAMP-dependent alterations in Ca2+-signaling 
by CAA in human proximal tubule cells in primary culture [20]. CAA acts as a sulfhydryl 
reagent and thereby impairs the proper function of proteins necessary for the balance of 
proliferation and apoptosis by inhibition of caspases. We could also show that CAA inhibits 
cathepsin B, a lysosomal cysteine protease of importance for digestion of endocytosed 
protein [21]. Depletion of non-protein-sulfhydryl groups such as reduced glutathione 
(GSH) impairs the capacity of the cells to scavenge free radicals, thereby increasing the 
susceptibility to oxidative stress. The latter mechanism should account for acute toxicity 
that is frequently observed during IFO-infusion. It may also be a mechanism of antitumor 
action of ifosfamide [22]. Consequently, providing alternative free sulfhydryl group-carrying 
molecules protects renal cells in culture (GSH, mesna or cysteine [19, 23]) and probably also 
in vivo (by N-acteylcysteine in combination with its antioxidative action [24]). Inhibition of 
cysteine proteases and disturbed Ca2+-handling do not necessarily lead to acute renal cell 
death, but are capable to induce chronic functional modifications leading to proximal tubule 
cell dysfunction, finally resulting in organ damage.
There are several case reports of pediatric and adult patients who developed chronic 
IFO-nephrotoxicity presenting as tubulointerstitial nephritis and fibrosis [25-27]. The 
hallmarks of chronic tubulointerstitial nephritis are chronic inflammatory events and altered 
extracellular matrix composition, which reinforce each other [28]. This vicious circle leads 
to epithelial mesenchymal transdifferentiation of proximal tubule cells, resulting in renal 
fibrosis in combination with impaired organ function. The major players in tubulointerstitial 
fibrosis are the fibrillar collagens type I and type III, which are often found to be increased in 
fibrotic disease [29]. Increases in collagen type IV as a constituent of the basal membrane are 
considered to be responsible for glomerular basement thickening, as it is found in diabetic 
nephropathy [30].
The purpose of this study was to identify possible profibrotic effects in human renal 
cells provoked by CAA and the signaling mechanisms involved. To work with a cell culture 
model in proximity to the clinical situation, human renal proximal tubule cells in primary 
culture (RPTEC) were used.
Materials and Methods
Cell culture
Human renal proximal tubule epithelial cells in primary culture (RPTEC) were purchased from 
Clonetics® (Cambrex Bioproducts) via CellSystems®, 53562 St. Katharinen, Germany. Cells were cultivated 
in plastic culture dishes (growth area 75 cm2) in Ham F-12/Dulbecco's modified Eagle's medium (DMEM), 
supplemented with 1.1 g/l NaHCO3, 3.57 g/l 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES), 
5 mg/l human apo-transferrin, 5 mg/l (bovine)insulin, 500 µg/l hydrocortisone, 10 µg/l mouse EGF, 5 µg/l 
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Na+-selenite, 0.5% fetal calf serum (Biochrom, Berlin, Germany), 6.5 µg/l thyroxin and 500 µg/l epinephrine 
under standard cell culture conditions (37 °C, 5% CO2). The medium was changed 3 times a week and the 
cells were subcultivated every 14 days. In order to work with well differentiated cells, RPTEC were used for 
experiments from passage 5 to 9 [20]. These cells express the mRNA of organic anion transporters OCT1 and 
OCT2 but not of OCT3 (SLC22A1, SLC22A2 and SLC22A3, resp.) as confirmed by PCR and qRT-PCR.
Determination of collagen secretion by direct ELISA
Collagen I, III and IV secretion was determined by enzyme-linked immunosorbent assay (ELISA). 
According to [31], media and collagen standards (Sigma) were incubated overnight at 4 °C in 96-well Nunc-
Immuno Maxisorb plates (Nalge Nunc International, Naperville, IL, USA). Following washing and blocking (2 
h in 2 % bovine serum albumin in PBS/Tween 0.05 %), wells were incubated with rabbit antibody against 
collagen I, III or IV (1:1000, Rockland, Gilbertsville, PA) for 1 h at room temperature. After three washes, 
wells were incubated with HRP-conjugated secondary antibody (1:20000; Rockland, Gilbertsville, PA) for 
1 h at room temperature and thereafter, after washing, incubated with o-phenylenediamine solution (0.5 
mM o-phenylenediamine, 150 mM Na2HPO4, 3.5 mM citric acid, 0.015% H2O2) and the reaction was stopped 
after 15 min with 1 N H2SO4. The absorbance at 490 nm was determined using a multiwell-multilabel 
reader (Viktor2, Wallac, Turku, Finland). Collagen secretion was normalized to total cellular protein content 
determined by the BCA-Assay [32].
Determination of intracellular collagen by western blotting
Cells were lysed in ice-cold buffer (1 mM Na-orthovanadate, 1% Nonidet P-40, 0.1% SDS, 0.1% Triton 
X-100, protease inhibitor cocktail, in PBS), protein therein determined and equal protein amounts were 
separated by SDS-PAGE and transferred onto a nitrocellulose membrane. Subsequently, membranes were 
blotted with either rabbit anti-collagen type III or IV antibody (1:1000, Rockland, Gilbertsville, PA via 
Biotrend, Cologne, Germany). The primary antibody was detected using horseradish-peroxidase-conjugated 
secondary IgG (1:20 000) visualized by ECL. Protein bands were quantified using SigmaGel software (Jandel 
Scientific).
Determination of gelatinase activity
Gelatinase activity in cell culture media was determined as described in [33]. Shortly, the media were 
incubated with reaction Buffer (0.05 M Tris-Base, 150 mM NaCl, 5 mM CaCl2, 1 µM ZnCl2, 0.2 mM NaN3, pH 
7.6) and 1 µg FITC-labeled-gelatin (DQ-gelatin). Increase in fluorescence over time was determined at 37 
°C at 490/535 nm excitation/emission. 1-10 ng collagenase I (Clostridium histolyticum, Sigma) served as 
positive controls. The measured increase in fluorescence/time was normalized for protein content. Possible 
direct effects of CAA on collagenase I were also tested, since CAA is capable of direct modification of proteins 
[21]. We found no alterations in collagenase I activity after 4 h incubation of the enzyme with CAA up to 150 
µM.
Determination of CA-074 sensitive gelatinase activity
Contribution of cathepsin B to total gelatinase activity was determined by use of the cathepsin B 
inhibitor CA-074 (10 µM; Sigma). As described in the previous paragraph, two aliquots from cell culture 
supernatants were incubated with gelatinase assay reaction buffer containing either CA-074 or DMSO. 
After addition of 1 µg DQ-gelatine the effect of CA-074 on fluorescence increase over time was assessed. 
Fluorescence counts were normalized for control/DMSO and protein content. CA-074 did not affect the 
collagenase I controls.
Gelatin zymography
Gelatin zymography of cell culture media was performed using PAGE in 10 % polyacrylamide gels 
containing 0.5 % gelatin. Media (50 µl) were incubated for 30 min at 37 °C in Laemmli Buffer devoid of 
mercaptoethanol and subsequently underwent electrophoresis. Afterwards gels were washed in 2.5 % 
Triton X-100 in H2O for 1 h, followed by overnight incubation at 37 °C in enzyme buffer (50 mM TRIS; 10 
mM CaCl2, 1 µM ZnCl2, 0.1% Triton X-100, 3 mM NaN3, pH 7.5). After Comassie staining and destaining of the 
gels, areas of gelatinase activity appeared as nonstained, light bands. Afterwards, gels were dried, scanned 
and analyzed by SigmaGel-software. Intensity values were normalized to total cellular protein content.
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Determination of Cathepsin B activity
Cathepsin B activity was measured by means of the specific fluorescent substrate z-Arg-Arg-AMC 
(AMC: 7-amino-4-methyl-coumarin) [34]. After incubation for up to 3 h at 37°C, fluorescence of the cleavage 
product AMC was measured at 355 nm excitation and 460 nm emission. Activity was normalized to protein 
content.
PCR experiments
The mRNA of organic anion transporters SLC22A1, SLC22A2 and SLC22A3 (OCT1, OCT2 and OCT3) 
was detected by PCR and qRT-PCR using the following conditions and primers: 10 min 95°C followed by 45 
cycles with 10 seconds 95°C, 10 seconds 60°C and 30 seconds 72°C, in case of qRT-PCR followed by melting 
point determination. The quality of the primers (5´- 3´) has been validated by sequencing the unique 
amplificate found in cells overexpressing the resp. mRNAs.
SLC22A1 (OCT1), forward: ACATTCGTCAGGAACCTCGG
reverse: CGCCGCAAAACATCTCTCTC
SLC22A2 (OCT2), forward: GCTACGAGGTGGACTGGAAC
reverse: CTCCGATATCTCCGCCCAAC
SLC22A3 (OCT3), forward: GTTTTTGCTGCTGTGCCTGAC
reverse: TCCAGCATCCACGCATTGAC
Statistics
All data are presented as mean values ± S.E.M. For statistical testing prophet 5.0 software was used. 
The Shapiro-Wilks-test was performed to test data for normality (H0 was rejected when p < 0.05). When 
none of the tested samples failed the normality test, samples were compared by one-way ANOVA, otherwise 
by Kruskal-Wallis-test. Statistical significance was assumed when p < 0.05.
Results
Chloroacetaldehyde causes time- and dose-dependent alterations in extracellular matrix 
composition of renal cells
Following 24 h of serum starvation, human proximal tubule cells in primary culture 
were incubated for 24–48 h with CAA in concentrations from 15 up to 150 µM. According to 
literature, 15 µM resemble CAA levels detected in patient plasma during ifosfamide therapy 
[35]. Figures 1A and B show the effect of 15 µM and 150 µM CAA on extracellular matrix 
composition in RPTEC after 24 h and 48 h incubation. As shown in Figure 1A, 15 µM CAA 
induced a progredient increase in type III collagen (182.4 ± 13.8 % of control after 24 h and 
266.4 ± 46.2 % of control after 48 h), whereas collagen I was not affected (123.1 ± 9.1 % of 
control after 24 h and 99.7 ± 6.5 % of control after 48 h). Type IV collagen was reduced during 
the incubation period (80.2 ± 4.8 % of control after 24 h and 82.3 ± 5.4 % of control after 
48 h). When RPTEC were challenged with 150 µM CAA (Fig. 1B), a massive and progredient 
increase in secreted collagen III was observed (703.6 ± 108.2 % of control after 24 h and 
2286.2 ± 834.1 % of control after 48 h). Collagen I secretion was elevated but failed to be 
statistically significant (314.9 ± 44.1 % of control after 24 h and 302.1 ± 107.8 % of control 
after 48 h). Also, collagen type IV secretion was elevated (135.0 ± 14.9 % of control after 24 
h and 214.3 ± 82.6 % of control after 48 h). Yet, the effect of 150 µM CAA on type IV collagen 
failed to reach statistical significance. The parent compound ifosfamide (150 µM) and its 
metabolite acrolein (15 µM) failed to interfere significantly with RPTEC collagen secretion 
(not shown). These data show that CAA at clinical relevant concentrations enhances collagen 
III secretion of human renal proximal tubule cells in primary culture.
Western blot analysis of lysates from RPTEC showed slightly increased intracellular 
levels of collagen type III (Fig. 1C: 148.0 ± 27.2 % of control after 24 h and 256.3 ± 62.0 % of 
control after 48 h), whereas intracellular collagen IV was decreased after challenge with 15 
µM CAA (29.2 ± 7.1 % of control after 24 h and 40.2 ± 16.1 % of control after 48 h). Thus, the 
results indicate that altered intracellular collagen metabolism is involved in the changes of 
secreted collagen pattern caused by CAA.
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Chloroacetaldehyde alters activities of secreted collagenolytic and gelatinolytic enzymes
To test a possible interference of CAA with enzymes involved in matrix degradation, 
gelatinase activity was determined in media collected after CAA exposure. Furthermore, 
gelatin zymography was used to specify MMP´s possibly involved. Figure 2A shows that 
incubation with CAA caused an increase in total gelatinase activity 24 h after exposure of 
RPTEC to 150 µM CAA. After exposure to 15 µM CAA total gelatinase activity was slightly 
elevated after 48 h incubation (Fig. 2A; total gelatinase activity: 106.6 ± 7.9 % of control 
after 24 h and 118.8 ± 8.4 % of control after 48 h). 150 µM CAA led to an elevation of total 
gelatinase activity to 307.2 ± 60.0 % of control after 24 h and 327.1 ± 36.7 % of control after 
48 h, respectively. In the additionally performed gelatin zymography experiments (Fig. 2B 
and C) MMP-2 and MMP-9 were found to be predominantly secreted by RPTECs, with much 
higher MMP-2 activity rates than MMP-9 activity. The faint gelatinolytic band representing 
weak MMP-9 activity was unaltered by CAA treatment. To our surprise, MMP-2 activity was 
significantly reduced after CAA exposure for 24 h or 48 h (15 µM CAA reduced relative MMP-
2 activity to 41.1 ± 6.6 % of control after 24 h and to 33.8 ± 10.0 % of control after 48 h). 
In order to explain this discrepancy between the induction of total gelatinase activity and 
reduction of MMP-2 activity, we investigated the contribution of the lysosomal protease 
cathepsin B in CAA-treated RPTECs. Since CAA induces lysosomal protein overload and 
leakage of lysosomes [21], we further investigated the sensitivity of total gelatinase activity 
against the specific cathepsin B inhibitor CA-074. As shown in Figure 3A, CA-074 (10 µM) 
led to a significant reduction of total gelatinase activity in media of CAA-treated cells (15 µM 
CAA: 111.9 ± 14.6 vs. 77.5 ± 11.4 % of control; 150 µM CAA: 182.0 ± 19.8 vs. 101.4 ± 18.8 % 
of control), whereas no significant effect of CA-074 in media of control cells was observable 
(92.7 ± 6.4 % of control). To support this hypothesis, cathepsin B activity in cell culture 
Fig. 1. Effects of CAA on collagen secretion and in-
tracellular collagen III and collagen IV content of 
RPTEC. 15 µM (A) or 150 µM (B) CAA were applied 
and collagen content was determined in media after 
24 h and 48 h of exposure (n = 16 - 48; * p < 0.05 
vs. control). (C) Intracellular collagen content after 
exposure to 15 µM CAA. Insert shows a representa-
tive western blot against collagen III after 24 h 15 
µM CAA (n = 4 – 7; * p < 0.05 vs. control).
Fig. 2. (A) Total gelatinase activity in cell culture 
supernatants of RPTEC after 24 h and 48 h expo-
sure to 15 or 150 µM CAA (n = 8 – 26; * p < 0.05 vs. 
control). (B) Gelatin zymography of RPTEC media. 
Typical result with a faint gelatinolytic band repre-
senting MMP-9 and a solid band representing MMP-
2. (C) Quantification of MMP-2 and MMP-9 activity 
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media was determined. As shown in Figure 3B, a significant increase in media cathepsin B 
activity induced by CAA occurred (15 µM: 230.9 ± 77.7 % of control; 150 µM: 702.1 ± 273.9 
% of control). Under control conditions, media cathepsin B release was 0.44 ± 0.05 % of total 
cathepsin B activity. Thus, CAA inhibits MMP-2-activity, but due to concomitant cathepsin B 
leakage from the cells, total gelatinase activity is unchanged (15 µM CAA) or even enhanced 
(150 µM CAA). These data reveal a severe interaction of CAA with ECM turnover, since 
not only collagen secretion is disturbed by CAA, but also the balance of secreted matrix-
remodelling enzyme activities is heavily disordered.
Contribution of signaling pathways in CAA induced matrix derangement
Calcium and PKC
To identify mechanisms by which CAA affects ECM homeostasis of RPTEC, 
pharmacological approaches were used. Collagen III secretion by RPTEC was used as 
surrogate marker, because it was the most sensitive parameter after CAA treatment. 
Since CAA induces sustained increases of intracellular Ca2+ in RPTECs [20], the effect of 
intracellular Ca2+ chelation with BAPTA-AM on CAA induced collagen III secretion was 
examined. Incubation of RPTEC with BAPTA-AM (50 µM) reduced CAA induced collagen III 
secretion after 48 h incubation (Fig. 4). The use of the PKC inhibitors BIM I (500 nM) and 
rottlerin (10 µM) had no effect (data not shown). Thus, the effect of CAA on collagen type III 
secretion seems to be dependent on intracellular Ca2+ but not on PKC activation.
Role of PKA and cAMP signaling pathways
Earlier studies from our laboratory could show a dependence of CAA-induced Ca2+-
elevations in RPTEC on cAMP/PKA-signaling [20]. Therefore, the impact of the membrane 
Fig. 3. (A) Total gelatinase activity after 48 hours in 
cell culture supernatants of RPTEC in presence and 
absence of the cathepsin B inhibitor CA-074 (n = 16 
– 20; * p < 0.05 vs. DMSO; n.s. = not significant). (B) 
Cathepsin B activity in RPTEC media after 48 hours 
(n = 12 – 16; * p < 0.05 vs. control).
Fig. 4. Effect of calcium chelation by BAPTA-AM (50 
µM) on CAA-induced collagen III secretion after 48 
hours (n = 8; * p < 0.05 vs. control; # p < 0.05 vs. 150 
µM CAA).
Fig. 5. Influence of PKA-cAMP-signaling pathway 
on CAA-induced collagen III secretion. Cells were 
incubated for 48 hours with or without 15 µM 
CAA and 1 µM H-89, 500 µM IBMX or 1 mM cAMP 
(n = 6 - 8; * p < 0.05 vs. control; # p < 0.05 vs. 15 µM 
CAA).
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permeable cAMP-analogue dibutyryl-cAMP (db-cAMP; 1 mM), the phosphodiesterase-
inhibitor IBMX (isobutylmethylxanthine 0.5 mM) and the PKA-inhibitor H-89 (1 µM) were 
tested on collagen III secretion by RPTEC. Figure 5 shows the effects of H-89, IBMX and db-
cAMP on collagen III secretion in the presence or absence of 15 µM CAA. 48 h incubation 
with H-89 alone led to a significant increase in collagen type III production (295.7 ± 50.5 % 
of control), that was not further increased by CAA (306.8 ± 96.8 % of control). IBMX (168.9 
± 26.2 % of control) and db-cAMP (88.7 ± 12.2 % of control) did not significantly alter the 
amount of secreted collagen III, whereas both compounds potentiated the effect of CAA: 
IBMX + CAA increased type III collagen to 679.1 ± 66.0 % of control whereas CAA alone led to 
an increase to 194.5 ± 28.7 % of control. Coincubation of CAA and dibutyryl-cAMP elevated 
collagen III secretion to 730.8 ± 99.4 % of control. Thus, there is evidence for a contribution 
of the cAMP/PKA-signaling pathway in CAA-induced collagen type III secretion.
Extracellular pH and sulfhydryl-ractivity
Since acute CAA toxicity can be partly reduced by extracellular acidification due to 
reduced sulfhydryl reactivity of the compound in acidic environment [21], the effects of 
lowering extracellular pH on collagen III secretion provoked by CAA was investigated. Figure 
6 shows the amount of extracellular collagen III in acidified media (pHo 7.2 or 6.9) of RPTEC 
after 48 h CAA exposure. The extracellular acidification per se had no significant effect on 
collagen type III secretion. At pHo 7.2, 15 µM CAA led to an increase of collagen III to 245 ± 
100 % of control and to 1445 ± 666 % of control when 150 µM CAA were used. At pHo 6.9, 
collagen III secretion was 150 ± 50 % of control in presence of 15 µM CAA and 278 ± 89 % of 
control after challenge with 150 µM CAA. These results indicate a reduced effect of CAA on 
collagen type III secretion in an acidic extracellular environment.
Protein challenge aggravates CAA-induced collagen III increase
The effects of CAA with regards to changes in lysosomal morphology and permeability 
could be enhanced by additional protein challenge [21]. Therefore, a possible contribution of 
an elevated protein load on collagen III secretion in response to CAA was investigated. After 
24 h exposure to 15 or 150 µM CAA, RPTEC were challenged by 1 g/l bovine serum albumin 
for additional 24 h. The results are summarized in Figure 7. BSA alone led to an increase in 
type III collagen to 986 ± 325 % of control according to known effects of protein challenge 
on proximal tubule cells [36]. Addition of BSA to cells exposed to CAA induced an increase of 
collagen III already at 15 µM CAA and up to 7093 ± 2058 % of control (150 µM CAA). Thus, 
CAA-induced collagen III secretion can be potentiated by protein overload.
Fig. 6. Extracellular pH-dependent CAA-
evoked collagen III secretion after 48 hours. 
(n = 6 - 14; * p < 0.05 vs. control; # p < 0.05 vs. 150 
µM CAA).
Fig. 7. Effect of protein load on CAA-induced 
collagen III formation. RPTEC were incubated 
with 15 or 150 µM CAA for 24 h and afterwards 
challenged with 1 g/l bovine serum albumin 
(BSA / BSA+CAA) for another 24 h (n = 8; 
* p < 0.05 vs. control; # p < 0.05 vs. CAA).
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The data presented here show that the ifosfamide metabolite chloroacetaldehyde is a 
potent profibrotic agent in renal proximal tubule cells in primary culture. We tested also 
its parent compound, ifosfamide, which turned out to have no profibrotic action although 
we were able to demonstrate the mRNA expression of IFO-transporting organic cation 
transporters [37] SLC22A1 and SLC22A2 (OCT1 and 2) but not SLC22A3 (OCT3) and although 
the presence of certain IFO-metabolizing cytochrome P450 enzymes at least in tubular cells 
of the developing kidney has been shown [13]. Obviously, either ifosfamide was not taken up 
sufficiently or not metabolized to a sufficient amount to exert the effects which has CAA on 
extracellular matrix homeostasis described here.
The effect of CAA is predominantly characterized by a marked increase in type III 
collagen synthesis and a decrease in type IV collagen in cells of proximal tubule origin. These 
data point towards extracellular matrix disarrangement provoked by CAA, which on the one 
hand leads to deposition of fibrillar collagen type III, associated with fibrosis, inflammatory 
events and wound healing. The decrease in type IV collagen could reflect reduction of 
epithelial tightness by impaired composition of basal membranes, negatively influencing 
tubular transport mechanisms. These results are in good agreement with case reports from 
patients who developed chronic ifosfamide nephrotoxicity presenting as tubulointerstitial 
fibrosis [25-27].
To distinguish between enhanced synthesis of type III collagen and reduction in matrix 
degradation induced by CAA, western blot analysis of intracellular collagen was performed and 
gelatinase/matrix metalloproteinase activity in media of CAA treated cells was determined. 
The data show that CAA exposure led to an increase of intracellular collagen III as well as a 
reduction in intracellular collagen IV immunoreactivity, in accordance to extracellular matrix 
alteration evoked by CAA. Total gelatinolytic capacity, determined by gelatinase-assay, was 
Fig. 8. Scheme of the putative pro-
fibrotic action mechanism of CAA. 
1: CAA disturbs signaling via cAMP-
PKA and intracellular Ca2+ leading to 
an increase of intracellular collagen 
III. 2. CAA induces lysosomal protein 
overload and leakage, further 
promoting collagen synthesis. 
Cathepsin B released from lysosomes 
cleaves intra- and extracellular collagen 
IV. 3. Reduced MMP-2 activity further 
aggravates extracellular collagen III 
accumulation. Extracellular cathepsin 
B exacerbates ECM disturbance by 
further collagen IV depletion. 
Table 1. Summary of CAA effects on the parameters 
tested in this study
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not reduced by CAA. Nevertheless MMP-2 activity, determined by gelatin zymography was 
reduced. These apparently conflicting results can be explained by increased cathepsin B 
activity in RPTEC supernatants, most probably due to release of cathepsins from ruptured 
lysosomes as well as other collagenolytic proteases that can access the extracellular space 
due to CAA-induced membrane disruption. The increased cathepsin B activity measured in 
RPTEC media after CAA exposure coincided with an increasing fraction of gelatinase sensitive 
to the specific cathepsin B-inhibitor CA-074. In a previous study, we could show lysosomal 
leakage after CAA exposure in coincidence with increased cell membrane permeability [21]. 
It is known, that amongst lysosomal proteases especially cathepsin B can be stable and active 
in the extracellular space under non-acidic conditions [38].
As shown previously [20], CAA is capable to interfere with Ca2+- and cAMP-PKA-signaling. 
Thus, the possible contribution of these signaling pathways on CAA-induced collagen type 
III synthesis was investigated. Chelation of intracellular free Ca2+ by BAPTA-AM reduced 
collagen III accumulation in response to CAA. These results point towards an involvement of 
Ca2+ in the fibrotic action of CAA probably including calcium-dependent kinases or calcium-
calmodulin complexes. Furthermore, chelation of Ca2+ by BAPTA-AM is able to reduce the 
CAA-invoked collagen III synthesis even when CAA is used in a concentration of 150 µM. 
Since Ca2+-chelation prevents protein loss induced by 15 µM CAA, but not by 150 µM CAA 
[20], it can be speculated that Ca2+ is a signal transducer for chronic CAA effects, such as 
fibrosis, but not for the toxic effects of high CAA concentrations that are most probably a 
direct effect of thiol-group depletion [23]. Additionally, involvement of the cAMP-PKA-
pathway in enhanced collagen III formation was investigated. Inhibition of PKA by H-89 
abrogated the effect of CAA on collagen type III, whereas stimulation of adenylyl cylclase by 
db-cAMP and inhibition of phosphodiesterases by IBMX potentiated CAA-induced collagen 
III synthesis. These data implicate that the cAMP-PKA pathway is involved in the increased 
extracellular type III collagen secretion in response to CAA.
In order to investigate the possibility that extracellular acidification could be a prevention 
method for the profibrotic effects of CAA, the effect of CAA on collagen III was determined 
after lowering extracellular pH. As previously reported, the ability of CAA to react with 
sulfhydryl groups is reduced by acidification in vitro [21]. Reducing extracellular pH from 
7.2 to 6.9 diminishes the profibrotic action of CAA. This is most probably due to impaired 
SH-reactivity by CAA. In addition, inhibition of cathepsin B activity by CAA is lessened when 
cells are exposed to CAA in acidic media. Taken together, these results point towards SH-
reactivity of CAA as a cause for the fibrotic effects, especially inhibition of lysosomal protein 
degradation which leads to cellular protein overload.
Additionally, protein overload can contribute to chronic renal damage by CAA. When 
human proximal tubule cells are challenged with BSA after CAA exposure, the profibrotic 
effects of CAA are potentiated, indicating that inhibition of lysosomal cysteine proteases by 
CAA worsens the effect of protein challenge. Thus, there is evidence for disturbed protein 
handling by proximal tubular cells after CAA exposure. In proteinuria-induced proximal 
tubular damage, free radicals play a major role in progression of fibrosis. In order to test 
the contribution of free radicals to CAA-induced type III collagen synthesis, the radical 
scavenger tiron was used. In these experiments, no positive effect of tiron could be observed 
on collagen III accumulation as well on LDH-release (data not shown). These results are in 
accordance with data published on CAA-toxicity in osteosarcoma cells [22].
In conclusion, this study shows that the ifosfamide metabolite CAA is able to induce 
extracellular matrix alterations in human proximal tubule cells in primary culture. The 
predominant feature is an increase in collagen III, which is due to enhanced synthesis of 
type III collagen accompanied by a decrease in MMP-2 activity. The effect of CAA on collagen 
III depends on intracellular free Ca2+ and cAMP-PKA signaling. Protein challenge aggravates 
the fibrotic effect of CAA. Reducing sulfhydryl reactivity of CAA by acidification ameliorates 
CAA-induced fibrosis. Thus, there is evidence for chronic alterations in proximal tubule cell 
homeostasis by CAA that could translate into the clinically observed chronic and progredient 
course of ifosfamide nephropathy.
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